Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clene Inc. filings document regulatory, financing, governance and operating disclosures for a late clinical-stage biopharmaceutical company focused on neurodegenerative diseases. Form 8-K reports cover CNM-Au8 clinical and regulatory communications, operating and financial results, securities purchase agreements, warrant terms and grant-related subaward agreements supporting ALS expanded access activity.
Proxy materials describe annual meeting proposals, director elections, auditor ratification and other shareholder voting matters. The filing record also addresses capital-structure changes, material agreements, Regulation FD disclosures, intellectual-property provisions tied to research funding, clinical and regulatory disclosures, and the role of Clene Nanomedicine Inc. in the company’s development programs.
Clene Inc. (CLNN) reported an amended Form 4 showing an option grant to Robert Dee Etherington, President & CEO and director. The amendment corrects the exercise price to $5.88 per share for an option covering 40,000 shares of common stock granted on 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan. The options vest in 12 equal monthly installments beginning 10/25/2025 and expire on 09/24/2035. The filing was signed by Jerome T. Miraglia as POA on 09/30/2025.
Clene Inc. reporting person Morgan R. Brown, Chief Financial Officer, filed an amended Form 4 to correct details of an option grant. The amendment states a stock option for 10,000 shares of common stock was granted on 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan with a corrected exercise price of $5.88 per share. The options vest in 12 equal monthly installments beginning 10/25/2025 and fully vest after 12 months. The amendment corrects a previously filed Form 4 dated 09/29/2025 and was signed by POA on 09/30/2025. The filing reflects an insider compensation-related equity award with a defined vesting schedule and a specified exercise price.
Clene Inc. (CLNN) reporting person Mark Mortenson, Chief Science Officer, was granted a stock option for 40,000 shares on 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.05 per share. The option vests in 12 equal monthly installments beginning 10/25/2025 and is exercisable through 09/24/2035. The Form 4 was filed as a single reporting person filing and signed by a power of attorney, Jerome T. Miraglia, on 09/29/2025. The filing shows the reporting person will directly own 40,000 underlying shares following the grant.
Clene Inc. insider grant: Robert Dee Etherington, President & CEO and director of Clene Inc. (CLNN), was granted an option for 40,000 shares of common stock on 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan with an exercise price of $6.05 per share. The option has an exercise price of $6.05 and an expiration date of 09/24/2035.
The option vests in 12 equal monthly installments beginning 10/25/2025 (25th of each month) until fully vested. The Form 4 was filed by one reporting person and signed via POA by Jerome T. Miraglia on 09/29/2025. Following the grant, Etherington beneficially owns 40,000 underlying shares subject to the option, held directly.
Clene Inc. reporting person Morgan R. Brown, who is identified as an officer (Chief Financial Officer), was granted a stock option award on 09/25/2025 for 10,000 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.05 per share. The award vests in 12 equal monthly installments starting 10/25/2025 until fully vested. The table lists the underlying common shares as 10,000 and shows the option term referencing 09/24/2035. The Form 4 reports the grant as an acquisition of derivative securities and indicates direct ownership following the grant of 10,000 options.
Clene Inc. presented new clinical data at ECTRIMS 2025 showing CNM-Au8 improves brain energy metabolism in multiple sclerosis patients. The company furnished a poster as Exhibit 99.1 and a press release as Exhibit 99.2 in an 8-K dated September 25, 2025. The filing states the furnished materials are incorporated by reference for disclosure purposes but are not "filed" under Section 18 of the Exchange Act. No numerical efficacy, patient counts, statistical measures, or detailed clinical results are included in the text of this Current Report.
Clene Inc. reported an insider grant: Robert Dee Etherington, who is listed as both a director and the President & CEO, received a grant of option rights to purchase 10,000 shares of common stock on 09/18/2025 under the Clene Amended 2020 Stock Plan at an exercise price of $6.32 per share. The options vest immediately, are exercisable as granted, and expire on 09/17/2035. The filing shows direct beneficial ownership of the 10,000 underlying shares following the grant. The Form 4 was signed by a power of attorney on 09/19/2025.
Clene Inc. reported a compensation-related insider transaction: Chief Financial Officer Morgan R. Brown received a stock option for 10,000 shares of common stock with an exercise price of $6.32 per share. The option grant was dated 09/18/2025 and is exercisable through 09/17/2035. The filing states the options vest immediately upon grant, and following the grant the reporting person beneficially owns 10,000 underlying shares through the option. The grant was made under the company’s Amended 2020 Stock Plan.
Mark Mortenson, Chief Science Officer of Clene Inc. (CLNN / reported symbol CLNNW), was granted a stock option for 10,000 shares of common stock on 09/18/2025. The option has an exercise price of $6.32 per share, vests immediately upon grant, and expires on 09/17/2035. Following the grant, the filing reports beneficial ownership of 10,000 underlying shares attributable to the option. The Form 4 was signed by a power of attorney, Jerome T. Miraglia, on 09/19/2025. The filing indicates it was submitted by one reporting person and lists the reporting person’s Salt Lake City address.
Clene Inc. has an ongoing equity distribution agreement with Canaccord Genuity LLC dated April 28, 2025, authorizing offers and sales of up to $25,000,000 of common stock. Through this program the company previously sold common stock totaling approximately $3,706,213. On September 5, 2025 Clene filed a prospectus supplement adding $6,280,000 of additional shares available for sale under the agreement. The legal opinion from Holland & Knight LLP regarding the validity of the shares is filed as Exhibit 5.1 and is incorporated by reference.